Table 1.
Baseline characteristics of participants (n = 38) included in the analysis.
| Characteristic | −KES | +KES | p Value |
|---|---|---|---|
| Sex (male/female) | 8/10 | 10/10 | 0.757 |
| ECOG (0/1) | 16/2 | 18/2 | >0.999 |
| Stage (III/IV) | 9/9 | 10/10 | >0.999 |
| Age at entry, mean ± SD | 67.50 ± 9.40 | 68.95 ± 9.34 | 0.637 |
| BMI (kg/m2), mean ± SD | 21.37 ± 2.59 | 22.68 ± 3.14 | 0.069 |
| Extracellular water–total body water ratio (ECW/TBW), mean ± SD | 0.39 ± 0.01 | 0.39 ± 0.01 | 0.512 |
| PhA, mean ± SD | 4.48 ± 0.46 | 4.46 ± 0.57 | 0.922 |
| Alb (g/dL), mean ± SD | 3.76 ± 0.36 | 3.67 ± 0.50 | 0.525 |
| CRP (mg/dL), mean ± SD | 0.62 ± 1.33 | 1.43 ± 1.88 | 0.080 |
| Neutrophil (%), mean ± SD | 68.29 ± 10.15 | 69.48 ± 12.34 | 0.767 |
| Lymphocytes (%), mean ± SD | 23.31 ± 8.88 | 21.38 ± 9.13 | 0.857 |
| NLR, mean ± SD | 3.48 ± 1.73 | 5.28 ± 7.17 | 0.989 |
| CA19-9 (Log10(CA19-9)), mean ± SD | 2.89 ± 1.66 | 2.81 ± 1.31 | 0.874 |
−KES, the group that did not receive 1-kestose; +KES, the group that was administered 1-kestose.